On 5 August, the US Food and Drug Administration (FDA) granted approval to Moderna’s mRNA-based flu vaccine, mFLUSIVA, for adults aged 50–64, and accelerated approval for adults 65 and older. Moderna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results